Contrasting Xenetic Biosciences (XBIO) and Its Peers

Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Xenetic Biosciences to related businesses based on the strength of its valuation, earnings, risk, analyst recommendations, dividends, profitability and institutional ownership.

Profitability

This table compares Xenetic Biosciences and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xenetic Biosciences -123.72% -58.97% -49.54%
Xenetic Biosciences Competitors -12,516.26% -215.37% -31.41%

Earnings and Valuation

This table compares Xenetic Biosciences and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Xenetic Biosciences $2.98 million -$2.68 million -0.99
Xenetic Biosciences Competitors $693.62 million $7.98 million -18.37

Xenetic Biosciences’ competitors have higher revenue and earnings than Xenetic Biosciences. Xenetic Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Xenetic Biosciences has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500. Comparatively, Xenetic Biosciences’ competitors have a beta of -1.85, meaning that their average share price is 285% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Xenetic Biosciences and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenetic Biosciences 1 0 0 0 1.00
Xenetic Biosciences Competitors 9920 15335 45741 1601 2.54

As a group, “Biotechnology” companies have a potential upside of 110.31%. Given Xenetic Biosciences’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Xenetic Biosciences has less favorable growth aspects than its competitors.

Summary

Xenetic Biosciences competitors beat Xenetic Biosciences on 9 of the 12 factors compared.

Xenetic Biosciences Company Profile

(Get Free Report)

Xenetic Biosciences, Inc. is a biotechnology company focused on developing immuno-oncology treatments. Its XCART platform is designed to create personalized CAR T-cell therapies that recognize tumor-specific antigens on B-cell lymphomas, with the goal of targeting cancer cells while limiting effects on healthy cells. The company’s earlier work included PolyXen, a drug-delivery platform based on polysialic acid that was designed to extend the time biologic medicines remain in the body. Xenetic’s current stated focus is advancing its XCART technology and related product candidates.

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.